Jeremy Presland

Immunology and Microbiology · Life Sciences

13h-index1.1kcitations46works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(14), Receptor Mechanisms and Signaling(9), Cancer Immunotherapy and Biomarkers(8), Monoclonal and Polyclonal Antibodies Research(7), Adenosine and Purinergic Signaling(6)

Publications46 total

Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity
Molecular Biology Reports·2025Open Access
Abstract IA013: Discovery of the dual A2A/A2B receptor antagonist MK-1088 for the treatment of solid tumors
Molecular Cancer Therapeutics·2024Open Access
Abstract PR017: Discovery and clinical evaluation of a potent and selective A2A/2B dual receptor antagonist
Molecular Cancer Therapeutics·2023
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Abstract 3143: RIG-I agonism promotes immune activation in syngeneic tumor model
Cancer Research·2022
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
Journal of Medicinal Chemistry·2022· 124 citedOpen Access
Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery
SLAS DISCOVERY·2021· 1 citedOpen Access
Structural insights on ligand recognition at the human leukotriene B4 receptor 1
Nature Communications·2021· 22 citedOpen Access
An orally available non-nucleotide STING agonist with antitumor activity
Science·2020· 611 cited
page 1 of 3Next →

Frequent Co-authors

Ian Knemeyer(20), Jared N. Cumming(18), George H. Addona(18), Bo‐Sheng Pan(16), Samanthi A. Perera(16), Jennifer Piesvaux(16), Sašo Čemerski(16), Johnny E. Kopinja(16), Jason Laskey(16), Brian J. Long(16), B. Wesley Trotter(15), Ellen C. Minnihan(15), Hyun Chong Woo(15), Sharad Sharma(14), David Jonathan Bennett(14), Kalyan Chakravarthy(14), Archie Tse(14), Sheila Ranganath(14), Yiping Chen(13), Heidi M. Ferguson(13)